News

Covalent Werner helicase inhibitor shows clinical proof-of-concept in Phase I trial
For patients with cancers harboring certain genetic defects, the first-in-class targeted therapy RO7589831, which targets the DNA repair enzyme Werner helicase, demonstrated early signals of efficacy ...
EurekAlert!17d
AACR: First-in-class covalent Werner helicase inhibitor shows clinical proof-of-concept in Phase I trial
RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors. Drug works similarly to ...
IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of ...
AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists
AIM ImmunoTech Inc. (NYSE American: AIM) (OTC Pink: AIMI) (“AIM” or the “Company”) today announced the presentation of ...
The Manila Times5d
Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, ...
American Association of Individual Investors8d
Why Assembly Biosciences, Inc.’s (ASMB) Stock Is Down 5.02%
Assembly Biosciences, Inc.’s ASMB share price has dipped by 5.02%, which has investors questioning if this is right time to ...
Method Maps and Measures the Structure of RNA As It Develops
Yale researchers have now developed a method to map and measure the structure of RNA as it develops, an advance that may help ...